Abstract
Several epigenetic alterations leading to constitutively active mitogenic and cell-survival signaling, and loss of apoptotic response are causally involved in self-sufficiency of prostate cancer (PCA) cells toward uncontrolled growth, and increased secretion of pro-angiogenic factors. Therefore, one targeted approach for PCA prevention, growth control and / or treatment could be inhibition of epigenetic molecular events involved in PCA growth, progression and angiogenesis. In this regard, silibinin / silymarin (silibinin is the major active compound in silymarin) has shown promising efficacy. Our extensive studies with silibinin / silymarin and PCA cells have shown the pleiotropic anticancer effects leading to cell growth inhibition in culture and nude mice. The underlying mechanisms of silibinin / silymarin efficacy against PCA involve alteration in cell cycle progression, and inhibition of mitogenic and cell survival signaling, such as epidermal growth factor receptor, insulin-like growth factor receptor type I and nuclear factor kappa B signaling. Silibinin also synergizes the therapeutic effects of doxorubicin in PCA cells, making it a strong candidate for combination chemotherapy. Silibinin / silymarin also inhibits the secretion of proangiogenic factors from tumor cells, and causes growth inhibition and apoptotic death of endothelial cells accompanied by disruption of capillary tube formation on Matrigel. More importantly, silibinin inhibits the growth of in vivo advanced human prostate tumor xenograft in nude mice. Recently, due to its non-toxic and mechanismbased strong preventive / therapeutic efficacy, silibinin has entered in phase I clinical trial in prostate cancer patients.
Keywords: Prostate Cancer, epigenetic, silymarin, endothelial, pleiotropic
Current Cancer Drug Targets
Title: Prostate Cancer Prevention by Silibinin
Volume: 4 Issue: 1
Author(s): Rana P. Singh and Rajesh Agarwal
Affiliation:
Keywords: Prostate Cancer, epigenetic, silymarin, endothelial, pleiotropic
Abstract: Several epigenetic alterations leading to constitutively active mitogenic and cell-survival signaling, and loss of apoptotic response are causally involved in self-sufficiency of prostate cancer (PCA) cells toward uncontrolled growth, and increased secretion of pro-angiogenic factors. Therefore, one targeted approach for PCA prevention, growth control and / or treatment could be inhibition of epigenetic molecular events involved in PCA growth, progression and angiogenesis. In this regard, silibinin / silymarin (silibinin is the major active compound in silymarin) has shown promising efficacy. Our extensive studies with silibinin / silymarin and PCA cells have shown the pleiotropic anticancer effects leading to cell growth inhibition in culture and nude mice. The underlying mechanisms of silibinin / silymarin efficacy against PCA involve alteration in cell cycle progression, and inhibition of mitogenic and cell survival signaling, such as epidermal growth factor receptor, insulin-like growth factor receptor type I and nuclear factor kappa B signaling. Silibinin also synergizes the therapeutic effects of doxorubicin in PCA cells, making it a strong candidate for combination chemotherapy. Silibinin / silymarin also inhibits the secretion of proangiogenic factors from tumor cells, and causes growth inhibition and apoptotic death of endothelial cells accompanied by disruption of capillary tube formation on Matrigel. More importantly, silibinin inhibits the growth of in vivo advanced human prostate tumor xenograft in nude mice. Recently, due to its non-toxic and mechanismbased strong preventive / therapeutic efficacy, silibinin has entered in phase I clinical trial in prostate cancer patients.
Export Options
About this article
Cite this article as:
Singh P. Rana and Agarwal Rajesh, Prostate Cancer Prevention by Silibinin, Current Cancer Drug Targets 2004; 4 (1) . https://dx.doi.org/10.2174/1568009043481605
DOI https://dx.doi.org/10.2174/1568009043481605 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in On-line Absolute Trace Gas Analysis by SIFT-MS
Current Analytical Chemistry The Complexity of Omega-3 Fatty Acid Modulation of Signaling Pathways Related to Pancreatic Cancer
Current Medicinal Chemistry Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Implementing Cancer Exercise Rehabilitation: An Update on Recommendations for Clinical Practice
Current Cancer Therapy Reviews Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Emerging Anabolic Treatments in Osteoporosis
Current Drug Safety Nicotine, Body Weight and Potential Implications in the Treatment of Obesity
Current Topics in Medicinal Chemistry Magnetic Nanoparticles for MRI of Brain Tumors
Current Pharmaceutical Biotechnology Liposomal Targeting of Angiogenic Vasculature
Current Drug Delivery An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth
Current Radiopharmaceuticals High Catalytic Activity of Pd Nanoparticles Synthesized from Green Alga Chlorella vulgaris in Buchwald-hartwig Synthesis of N-Aryl Piperazines
Current Organocatalysis Antimutagenic Activity of Lutein –An Oxycarotenoid Present in the Macula and its Inhibition of Cytochrome P 450 Enzymes in vitro
Drug Metabolism Letters In Silico Methods for Predicting Ligand Binding Determinants of Cytochromes P450
Current Topics in Medicinal Chemistry CYP3A4 *1B Gene Polymorphism in Coronary Artery Disease Patients with Obesity Undergoing Statin Treatment
Current Pharmacogenomics and Personalized Medicine Development of Dry Powder Inhalers
Recent Patents on Drug Delivery & Formulation Abelson Tyrosine-Protein Kinase 1 as Principal Target for Drug Discovery Against Leukemias. Role of the Current Computer-Aided Drug Design Methodologies
Current Topics in Medicinal Chemistry Use of Corticosteroids in Critically Ill Septic Patients: A Review of Mechanisms of Adrenal Insufficiency in Sepsis and Treatment
Current Drug Targets ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design Synthesis of 2,5-Disubstituted-1,3,4-oxadiazole Analogs as Novel Anticancer and Antimicrobial Agents
Letters in Drug Design & Discovery Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design